CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,004 enrolled
Drug / intervention
Blood sample collectionprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02570152
NCT02570152N/ACompleted
CompareCT.gov

A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia

GlaxoSmithKline·interventional·Posted Oct 7, 2015·Updated Jul 7, 2020

In Brief

A clinical study evaluating Blood sample collection for Dengue. Completed, enrolled 2,004 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the incidence of dengue fever and to build capacity for dengue vaccine trials in dengue-endemic regions of South Asia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue
CountriesSri Lanka
CollaboratorsMinistry of Health, Sri Lanka

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 7, 2015
Enrollment StartJun 1, 2016
Primary CompletionJun 28, 2019
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.7 years ago

Interventions

Blood sample collectionprocedure

Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).